According to a recent LinkedIn post from Glooko, the company plans to showcase its integrated diabetes care technologies at the Becker’s Healthcare 16th Annual Meeting. The post highlights a combined offering that spans the inpatient EndoTool Glucose Management System, developed by Monarch Medical Technologies, and Glooko’s outpatient diabetes management platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that Glooko is positioning its portfolio as part of a “connected diabetes ecosystem” focused on interoperability, efficiency, and continuity of care across care settings. For investors, this emphasis on integrated solutions in both hospital and outpatient environments may indicate a strategy to deepen relationships with health systems and expand recurring software and services revenue opportunities.
By featuring Monarch Medical Technologies, described as a Glooko company, the post also underscores the company’s ongoing integration of acquired assets into a broader clinical workflow offering. If health systems adopt such end‑to‑end glucose management tools at scale, Glooko could strengthen its competitive position in digital diabetes management and potentially improve its long‑term growth profile within the healthcare IT and remote patient monitoring markets.